H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

November 19, 2025 6:38 AM EST Send to a Friend
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $41.00 price target on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login